Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment
Author:
Publisher
Springer Nature Singapore
Link
https://link.springer.com/content/pdf/10.1007/978-981-99-3746-2_19
Reference107 articles.
1. Akamatsu H, Teraoka S, Koh Y, Yamanaka T, Yamamoto N, Nakagawa K (2019) A phase II study of nivolumab in patients with advanced non–small-cell lung cancer who responded to prior PD-1/L1 inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clin Lung Cancer 20(2):139–141
2. Amini A, Byers LA, Welsh JW, Komaki RU (2014) Progress in the management of limited-stage small cell lung cancer. Cancer 120(6):790–798
3. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Calvo E (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (Checkmate 032): a multicenter, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895
4. Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Ottensmeier C (2016) Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol 11(9):1511–1521
5. Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Collins M (2003) Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 170(2):711–718
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3